Evaxion Biotech Bolsters MSD Vaccine Collaboration

Evaxion Biotech (EVAX) has released an update.

Evaxion Biotech has expanded its partnership with pharmaceutical giant MSD, providing MSD with the option to license two of Evaxion’s AI-designed preclinical vaccine candidates, EVX-B2 for Gonorrhea and EVX-B3 for an undisclosed infectious disease. Under the new agreement, Evaxion is set to receive an upfront payment of $3.2 million and could receive up to $592 million per product in milestone payments, plus royalties on sales. This collaboration underscores the industry’s confidence in Evaxion’s innovative AI-Immunology platform and its potential to develop effective vaccines.

For further insights into EVAX stock, check out TipRanks’ Stock Analysis page.